[CAS NO. 89786-04-9] Tazobactam

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [89786-04-9]

Catalog

HY-B1418

Brand

MCE

CAS

89786-04-9

DESCRIPTION [89786-04-9]

Overview

MDL	MFCD00867002
Molecular Weight	300.29
Molecular Formula	C10H12N4O5S
SMILES	O=C([C@@H]([C@@](CN1N=NC=C1)(C)S([C@]2([H])C3)(=O)=O)N2C3=O)O

For research use only. We do not sell to patients.

4 Publications Citing Use of MCE

Summary

Tazobactam (CL-298741) is a potent β-lactamases inhibitor and penicillin antibiotic . Tazobactam has antibacterial activity. Tazobactam can be used for pneumonia research ^[1] ^[2] .

In Vitro

Tazobactam (CL-298741) (5 μg/mL; 18 hours) has bactericidal activity and inhibit the growth of the bacteria in a dose-dependent manner ^[2] .
Tazobactam (CL-298741) (1-10 μg/mL; 6 hours; Prot. vulgaris and M. morgan ) inhibits various types β-lactamase activity and with ID ₅₀ values of ＜ 10 μg/mL, respectively ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tazobactam (CL-298741) (1000 mg/kg; i.p.; four times a day, for 36 and 84 hours; BALB/c mice) decreases the number of bacteria in mice and survived in low doses ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice ^[1]
Dosage:	1000 mg/kg
Administration:	Intraperitoneal injection; four times a day, for 36 and 84 hours
Result:	Decraesed the number of bacteria and neutrophils in BALF than in the control group.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04948463	Murdoch Childrens Research Institute	Febrile Neutropenia	November 15, 2021	Phase 4
NCT00003805	European Organisation for Research and Treatment of Cancer - EORTC	Bone Marrow Suppression\|Fever, Sweats, and Hot Flashes\|Infection\|Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Myelodysplastic Syndromes\|Unspecified Adult Solid Tumor, Protocol Specific\|Unspecified Childhood Solid Tumor, Protocol Specific	November 1997	Phase 3
NCT00389987	Merck Sharp & Dohme LLC	Complicated Intra-Abdominal Infections	September 2001	Phase 3
NCT03289351	Phoenix Children´s Hospital	Perforated Appendicitis\|Postoperative Infection	May 22, 2017	Phase 4
NCT03765645	Institute of Liver and Biliary Sciences, India	Antibiotic Prophylaxis\|Postoperative Infection	October 4, 2018	Not Applicable
NCT02817347	Yuhan Corporation	Otitis Media\|Otorrhea	June 2016	Phase 1\|Phase 2
NCT05608564	University of Belgrade	Periodontitis	January 17, 2022	Not Applicable
NCT05355350	Rambam Health Care Campus\|The Chaim Sheba Medical Center\|Rabin Medical Center\|Hadassah Medical Organization	Beta Lactam Resistant Bacterial Infection\|Enterobacteriaceae Infections\|Bacteremia	July 1, 2022	Phase 4
NCT02709382	Wockhardt\|Clinartis	Renal Impairment	March 2016	Phase 1
NCT03891433	Universidad del Norte	Urinary Tract Infections\|Enterobacteriaceae Infections\|Infection Due to ESBL Bacteria\|Carbapenem\|Escherichia Coli Infection\|Klebsiella Pneumoniae Infection\|Clinical Trial\|Drug Resistance, Bacterial	April 1, 2019	Phase 4
NCT03485950	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC\|National Cancer Institute (NCI)	Other Infectious Diseases	May 16, 2018	Phase 2
NCT04673175	Weill Medical College of Cornell University\|Merck Sharp & Dohme LLC	Pseudomonas Aeruginosa\|Pneumonia\|Hematologic Malignancy	July 20, 2022	Phase 1\|Phase 2
NCT01994993	Michael Cohen-Wolkowiez\|The Emmes Company, LLC\|Duke University	Complicated Intra Abdominal Infections	December 2013	Phase 2\|Phase 3
NCT03990467	Hospices Civils de Lyon	Septic Shock\|Sepsis\|Sepsis Syndrome	January 28, 2021	Not Applicable
NCT01667094	The Alfred	Cystic Fibrosis	September 2012	Phase 4
NCT01147640	Cubist Pharmaceuticals LLC	Complicated Intra-abdominal Infection	June 25, 2010	Phase 2
NCT02493764	Merck Sharp & Dohme LLC	Bacterial Pneumonia	November 24, 2015	Phase 3
NCT02473263	Assistance Publique - Hôpitaux de Paris	Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit	May 9, 2016	Phase 3

Appearance

Solid

Source

Gram-negative bacilli

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 166.51 mM ; Need ultrasonic)

H ₂ O : 1 mg/mL ( 3.33 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3301 mL	16.6506 mL	33.3011 mL
5 mM	0.6660 mL	3.3301 mL	6.6602 mL
10 mM	0.3330 mL	1.6651 mL	3.3301 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (6.93 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (6.93 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (6.93 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2S,3S,5R)-

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, [2S-(2α,3β,5α)]-

1H-1,2,3-Triazole, 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid deriv.

YTR 830H

Tazobactam

CL 298741